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Abstract
Background: The chemokine RANTES (regulated on activation, normal T-cell expressed and secreted)/CCL5 is involved in
the pathogenesis of cardiovascular disease in mice, whereas less is known in humans. We hypothesised that its relevance for
atherosclerosis should be reflected by associations between CCL5 gene variants, RANTES serum concentrations and protein
levels in atherosclerotic plaques and risk for coronary events.
Methods and Findings: We conducted a case-cohort study within the population-based MONICA/KORA Augsburg studies.
Baseline RANTES serum levels were measured in 363 individuals with incident coronary events and 1,908 non-cases (mean
follow-up: 10.264.8 years). Cox proportional hazard models adjusting for age, sex, body mass index, metabolic factors and
lifestyle factors revealed no significant association between RANTES and incident coronary events (HR [95% CI] for
increasing RANTES tertiles 1.0, 1.03 [0.75–1.42] and 1.11 [0.81–1.54]). None of six CCL5 single nucleotide polymorphisms and
no common haplotype showed significant associations with coronary events. Also in the CARDIoGRAM study (.22,000
cases, .60,000 controls), none of these CCL5 SNPs was significantly associated with coronary artery disease. In the
prospective Athero-Express biobank study, RANTES plaque levels were measured in 606 atherosclerotic lesions from
patients who underwent carotid endarterectomy. RANTES content in atherosclerotic plaques was positively associated with
macrophage infiltration and inversely associated with plaque calcification. However, there was no significant association
between RANTES content in plaques and risk for coronary events (mean follow-up 2.860.8 years).
Conclusions: High RANTES plaque levels were associated with an unstable plaque phenotype. However, the absence of
associations between (i) RANTES serum levels, (ii) CCL5 genotypes and (iii) RANTES content in carotid plaques and either coronary
artery disease or incident coronary events in our cohorts suggests that RANTES may not be a novel coronary risk biomarker.
However, the potential relevance of RANTES levels in platelet-poor plasma needs to be investigated in further studies.
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Introduction
Inflammation is one of the hallmarks of atherosclerosis [1].
Macrophage and lymphocyte recruitment and expression of
proinflammatory immune mediators characterise the initial stages
of atherogenesis, and inflammatory mechanisms also contribute to
progression of atherosclerosis and to plaque disruption at later
stages of the disease [2]. Although these immune-mediated
mechanisms are only partially understood, an increasing number
of studies indicates that chemokines are important mediators of
cardiovascular risk [3–6].
Chemokines are proinflammatory cytokines that recruit leuko-
cytes to sites of tissue damage or infection [7]. An interesting
candidate in this context is RANTES (regulated on activation,
normal T-cell expressed and secreted), also known as CCL5 (C-C
ligand 5) [8]. RANTES predominantly mediates chemotaxis and
activation of T cells, but also of monocytes, granulocytes, mast
cells and dendritic cells [9–13]. RANTES is mainly expressed by T
cells, but there are other important cellular sources such as
platelets, adipocytes, monocytes/macrophages and fibroblasts
[14,15]. Increased expression in adipose tissue and increased
serum concentrations of RANTES are associated with obesity,
type 2 diabetes and other cardiovascular risk factors [16–20].
Several lines of evidence indicate that RANTES plays a role in
the pathogenesis of cardiovascular diseases. In mice, RANTES is
expressed in atherosclerotic lesions and both RANTES antagonists
and deletion of the gene encoding the RANTES receptor CCR5
can reduce the progression of atherosclerosis or early myocardial
reperfusion [21–24]. In humans, the situation is less clear. Although
RANTES expression has been shown convincingly for the various
cell types in atherosclerotic plaques [reviewed in ref. 6], studies on
the relevance of circulating RANTES concentrations as biomarker
for cardiovascular risk are scarce. Moreover, population-based data
on the ability of RANTES levels to predict coronary events are
currently not available. Some reports on associations of polymor-
phisms in the genes encoding RANTES and CCR5 with coronary
artery disease (CAD) also support the notion that RANTES plays a
role in the development of cardiovascular disease [25].
We hypothesised that the relevance of RANTES in the
development of atherosclerosis should be reflected by associations
between CCL5 genotypes, systemic RANTES levels as well as
RANTES levels in atherosclerotic plaques and risk for coronary
events. We tested the first two parts of this hypothesis by assessing
the relationship between CCL5 gene (encoding RANTES protein)
variants and RANTES serum levels with cardiovascular risk in the
German MONICA/KORA Augsburg case-cohort study. In
addition, the association between CCL5 genotypes and CAD was
analysed in the large CARDIoGRAM study [26,27]. For the third
part of the hypothesis, we used carotid atherosclerotic plaques
from the Dutch Athero-Express biobank study. Recently, we
provided evidence that composition and biomarkers from carotid
plaques predict cardiovascular outcomes [28–31]. Therefore, we
investigated the associations between RANTES protein levels in
plaques with histological plaque phenotypes and conducted a
second prospective study to test whether local carotid RANTES
plaque levels were associated with future coronary events.
Materials and Methods
MONICA/KORA Augsburg case-cohort study: design,
population and follow-up
This study is a prospective case-cohort study [32] within the
population-based MONICA/KORA Augsburg studies [33–35].
Data were derived from three independent cross-sectional,
population-based surveys within the MONICA project in 1984/
1985 (S1), 1989/1990 (S2) and 1994/1995 (S3) in Augsburg
(Germany) and two adjacent counties. The studies were approved
by the local authorities and performed according to the
Declaration of Helsinki. The case-cohort study was approved by
the Bayerische Landesa¨rztekammer (Bavarian Medical Associa-
tion). All participants provided written informed consent.
Response rates for the different surveys were 75.7% (S1), 74.4%
(S2) and 73.1% (S3). The total number of study participants was
13,427 (6725 men, 6702 women) aged 25–64 (S1) or 25–74 years
(S2, S3). All subjects were prospectively followed within the
KORA framework until 2002.
The outcome variable ‘‘coronary events’’ was defined as
combined endpoint that consisted of incident non-fatal myocardial
infarction (MI) and fatal coronary death or sudden cardiac death
before the age of 75 years. Cases were identified through the
MONICA/KORA Augsburg coronary event registry. In addition,
follow-up questionnaires were sent to persons who had moved out
of the study area. Until December 2000, a major non-fatal MI was
diagnosed based on the MONICA algorithm (symptoms, cardiac
enzymes, ECG changes). Since January 2001 myocardial infarc-
tion was diagnosed according to criteria defined by the European
Society of Cardiology (ESC) and the American College of
Cardiology (ACC) [36,37]. Coronary deaths were validated by
autopsy reports, death certificates, chart review and information
from the last treating physician.
Due to the low incidence of coronary events in individuals
below 35 years of age, we limited the present study to persons aged
35–74 years at baseline (5382 men, 5336 women). Due to missing
blood samples, 1187 subjects had to be excluded which led to a
total source population of 9531 subjects (4696 men, 4835 women).
Participants with self-reported prevalent coronary heart disease
were also excluded, leading to a final source population of 9300
subjects (4507 men, 4793 women). For the case-cohort study, we
selected a random sample of the source population (called
subcohort) stratifying by sex and survey. The final stratum-specific
sample sizes of this subcohort were used together with the stratum-
specific sizes of the source population to compute sampling
fractions, and the inverse of the sampling fractions yielded the
survey and sex-specific sampling weights. All cross-sectional
analyses were performed in the subcohort which included 2077
subjects (1112 men, 965 women) after exclusion of subjects with
missing values for classical cardiovascular risk factors and essential
inflammatory markers. Until December 31, 2002, 397 study
participants had a coronary event according to our endpoint
definition (307 men, 90 women). After further exclusion of subjects
with incomplete information on relevant variables, the present
study was based on 2271 participants (280 men, 83 women with
incident coronary events; 976 men, 932 women who remained
event-free). The majority of cases (n = 318, 87.6%) occurred before
the end of 2000 when the diagnosis criteria were changed from the
MONICA algorithm to the ESC/ACC criteria. Cases with
incident coronary events included 175 participants with non-fatal
MI and 188 cases with fatal coronary death or sudden cardiac
death. The mean follow-up time (6 standard deviation) was
10.264.8 years.
Sociodemographic and lifestyle variables as well as data on
parental history of myocardial infarction were collected through
standardised interviews. Standardised medical examinations
including collection of a non-fasting venous blood sample for the
determination of biomarkers were performed. All procedures and
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routine laboratory methods have been described in detail
elsewhere [33–35].
MONICA/KORA Augsburg case-cohort study: laboratory
measurements
Serum levels of RANTES were determined using the Human
CCL5/RANTES Quantikine ELISA kit from R&D Systems
(Wiesbaden, Germany) as described [38]. Mean intra-/inter-assay
coefficients of variation were 4.2% and 5.1%, respectively, for
recombinant controls, and 4.1% and 6.4%, respectively, for test
sera.
Six single nucleotide polymorphisms (SNPs) were selected on
the basis of data from the International HapMap project (http://
www.hapmap.org) to obtain complete coverage of the CCL5 gene
for a 9.2-kb locus of the CCL5 gene (promoter: rs2107538
[2403G.A], rs2280788 [228C.G]; intronic: rs2280789,
rs4796120, rs3817655; 39-flanking region: rs1065341). All SNPs
were in Hardy-Weinberg equilibrium (p.0.2). Genotyping was
carried out with matrix-assisted laser desorption ionisation-time of
flight analysis of allele-dependent primer extension products as
reported [39]. A subset of samples (13.3%) was genotyped in
duplicate to assess genotyping quality. The mean discordance rate
for the six SNPs was 0.44%.
MONICA/KORA Augsburg case-cohort study: statistical
analysis
Baseline continuous characteristics of the study participants
were described using the SAS procedure SURVEYMEANS which
estimated standard errors appropriate to the sampling scheme.
Categorical variables and continuous variables were compared
between cases and non-cases by Wald chi-square test (SURVEY-
FREQ) and t tests on regression coefficients (SURVEYREG),
respectively. In case of non-normality, t tests were carried out for
log-transformed variables, and results were given as geometric
means with antilogs of standard errors of the adjusted log-means.
The associations of CCL5 genotypes and RANTES serum levels
with incident coronary events were assessed by Cox proportional
hazard models. The proportional hazards assumptions for the Cox
models were tested for all models graphically before the analyses
and demonstrated that proportional hazards can be assumed. The
case-cohort design required correction of the variance estimation
based on the sampling weights to give standard error estimates for
the parameter estimates. Correction for standard errors was made
using the method by Barlow [32]. The inverse of the sample sizes
for the subcohort by the cohort of interest yielded survey and sex-
specific sampling weights. If required we additionally differentiated
between cases and non-cases. Sex-specific tertiles of the weighted
distributions of RANTES serum levels in the subcohort were used.
Tests for trend were conducted assigning the median value within
each tertile to the corresponding tertile and including this variable
in the Cox regression model. A p value of,0.05 was considered to
be statistically significant for the analysis of RANTES serum levels.
For analyses regarding the 6 CCL5 genotypes, the significance level
was adjusted for multiple testing according to Bonferroni to 0.05/
6= 0.0083 for each SNP. All calculations were performed with
SAS (Version 9.1, SAS Institute Inc., Cary, NC, USA).
CARDIoGRAM study
The transatlantic CARDIoGRAM (Coronary ARtery DIsease
Genome-wide Replication And Meta-analysis) Consortium com-
bines data from 14 genome-wide association studies (GWAS)
comprising .22,000 cases with CAD and .60,000 controls, all of
European ancestry [26,27]. Cases and controls participated in
case-control or prospective cohort studies, and the case definition
in the participating studies comprised CAD, MI or both (see ref.
26 for a detailed list of studies and case/control definitions).
Genotype data were available from measurements on Affymetrix
and Illumina platforms with subsequent imputation of genotypes
in most studies [26]. The associations of CCL5 alleles with CAD
were assessed by calculating unadjusted odds ratios (OR) with
corresponding 95% CI and p values per specified allele. The
nominal significance level was adjusted for multiple testing
according to Bonferroni to 0.05/6= 0.0083 for each SNP in this
study. The level of genome-wide significance that corrected for all
tests performed in the GWAS was set at 561028.
Athero-Express biobank study: design, population and
follow-up
The Athero-Express study is an ongoing biobank study with a
longitudinal study design, comprising atherosclerotic plaques
obtained from patients who underwent carotid endarterectomy
(CEA) as described [40]. A multidisciplinary vascular team
reviewed all indications for surgery. For the present study we
included 606 atherosclerotic plaques from patients operated
between 24 March 2002 and 15 December 2006. The study
design has been reported previously [41]. All patients completed
questionnaires including medical history and medication use prior
to the operation. Patients who suffered from stroke, transient
ischemic attack (TIA) or amaurosis fugax (AFX) were considered
as symptomatic. Patients operated due to a significant stenosis of
more than 70% and without neurological manifestations were
considered as being asymptomatic. Hypertension and hypercho-
lesterolaemia were defined as use of anti-hypertensive drugs
(diuretics, beta blockers, calcium antagonists, ACE inhibitors,
angiotensin II antagonists) or cholesterol-lowering drugs (statins,
fibrates, acipimox, ezetimibe, colestyramine), respectively. After
surgery, patients were clinically followed for up to 3 years. The
composite endpoint was defined as fatal MI, sudden death, non-
fatal MI and coronary intervention (including coronary bypass and
coronary angioplasty). The medical ethics committees of the
participating hospitals (University Medical Center Utrecht,
Utrecht, and St Antonius Hospital Nieuwegein, The Netherlands)
approved the study, and all participants provided written informed
consent.
The collected atherosclerotic plaques were processed according
to a standardised protocol [41]. Briefly, plaques were cut into small
segments of 5 millimeters along the longitudinal axis. The segment
with the greatest burden was considered the culprit lesion, which
was subjected to histological assessment. Macrophage infiltration
(CD68) and smooth muscle cell infiltration (a-actin) were
quantified and expressed as percentage staining of the plaque
area using computerised analyses. In addition, calcification
(haematoxylin and eosin (H&E)), collagen content (Sirius Red) as
well as the macrophage and smooth muscle cell stainings were
scored semiquantitatively as ‘‘no’’, ‘‘minor’’, ‘‘moderate’’ or
‘‘heavy’’ staining [41]. The size of the lipid core (H&E and Sirius
Red) was visually estimated as the percentage of the total plaque
area, and plaque haemorrhage (fibrin) was scored as being present
or absent. Two independent observers performed the histological
examinations. The histological assessments showed good interob-
server reproducibility and the semi-quantitative examinations
correlated excellently with the computer-based assessments [42].
Athero-Express biobank study: laboratory measurements
The segments adjacent to the culprit plaque lesions were used
for protein isolation. Segments were dissolved in Tris buffer
according to a standardised protocol and quantified for the total
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amount of protein [41]. RANTES levels were quantified by a
multiplex assay from Bender MedSystems (Vienna, Austria)
according to the manufacturer’s protocol. RANTES levels were
corrected for total amount of protein within the segment.
Athero-Express biobank study: statistical analysis
Baseline RANTES levels in plaques were statistically analysed
by the non-parametric Mann Whitney-U test. The association of
RANTES expression with categorised histological plaque charac-
teristics was assessed using Spearman’s correlation test. The
association between plaque haemorrhage and RANTES expres-
sion was determined by the Mann Whitney U test.
We used unadjusted Cox regression analyses to determine the
association of RANTES plaque levels at baseline with cardiac
outcome during the follow-up. In order to exclude potential
confounding with respect to the association of RANTES plaque
levels and cardiac endpoint, we performed multivariate analyses
including all determinants that were significantly associated with
RANTES expression levels at baseline. The statistical analyses
were performed using SPSS 15.0 (SPSS Inc, Chicago, IL, USA).
Results
MONICA/KORA Augsburg case-cohort study
Individuals who experienced a coronary event during the
follow-up (cases) differed in most baseline characteristics from
individuals without incident coronary events (non-cases). Cases
were older, had a higher BMI, higher waist-to-hip ratio, higher
blood pressure, more frequently a history of hypertension or
diabetes, higher total and LDL cholesterol levels, lower HDL
cholesterol levels, higher ratio of total to HDL cholesterol, higher
systemic concentrations of CRP and IL-6, and were less frequently
physically active. These data have been reported before [43] and
are given in the supporting information (Table S1).
RANTES serum levels did not differ significantly between cases
and non-cases (mean 29.6 vs 28.0 ng/ml, p= 0.085). Cox
proportional hazard models showed that increasing tertiles of
RANTES serum concentrations were neither associated with
increased risk of coronary events after adjustment for age, sex and
survey (Table 1, model 1) nor after additional adjustment for
anthropometric, metabolic, immunological and lifestyle factors
(Table 1, models 2 and 3).
In order to assess whether RANTES serum levels may be more
informative for a shorter follow-up period, we repeated the
analysis for coronary events occurring in the first three years (84
cases, 2187 non-cases) or in the first five years (156 cases, 2115
non-cases). HRs (95% CIs) for increasing tertiles were 1.0, 1.10
(0.62–1.98) and 1.03 (0.57–1.86) for a follow-up time of three years
(ptrend = 0.90) and 1.0, 1.04 (0.67–1.61) and 1.06 (0.68–1.66) for a
follow-up time of five years (ptrend = 0.88) and thus very similar to
results obtained from the complete follow-up period.
Since we used non-fasting samples, we investigated the potential
impact of the duration of fasting on RANTES levels. Mean
duration of fasting did not differ between cases and non-cases,
RANTES levels did not correlate significantly with duration of
fasting in the subcohort (analysis adjusted for age, sex and survey),
and additional adjustment for this variable in model 3 had no
impact on HRs (data not shown).
Carriers of the minor alleles of the CCL5 SNPs rs2107538,
rs2280789, rs47966120 and rs3817655 had significantly lower
RANTES serum levels (padditive#3.1610
28) than carriers of the
major alleles in the MONICA/KORA subcohort, whereas no
differences were found for rs2280788 and rs1065341 as reported
previously [38]. In line with the data for serum levels, individuals
who were heterozygous or homozygous for the minor alleles of the
six SNPs investigated here had no decreased risk for coronary
events compared to study participants who were homozygous for
the respective major alleles (Table 2).
Based on the six aforementioned CCL5 SNPs, haplotypes were
constructed. None of the common haplotypes with frequencies of
$1% in the subcohort had a statistically significant impact on the
risk of coronary events compared to the most frequent haplotype
CCTATA (Table 3). However, individuals who carried any of the
rare haplotypes (frequencies ,1% in the subcohort) had a fourfold
increased risk of coronary events when these haplotypes were
analysed together compared to the carriers of haplotype
CCTATA (Table 3).
CARDIoGRAM study
Associations between the CCL5 SNPs rs2107538, rs2280788,
rs2280789, rs4796120, 3817655 and rs1065341 and CAD were
assessed in up to 82,387 individuals (.22,000 cases and .60,000
controls) in the CARDIoGRAM study (Table 4), but none of the
associations reached statistical significance.
Table 1. Risk of coronary events according to baseline serum concentrations of RANTES (MONICA/KORA Augsburg case-cohort
study).
HR (95% CI) for tertiles of RANTES (ng/ml)*
Tertile 1 Tertile 2 Tertile 3 p (trend)
Median [lower-upper limit] (men) 13.1 [2.7–17.7] 22.8 [17.7–29.2] 40.4 [29.2–176.0]
Median [lower-upper limit] (women) 13.6 [5.8–18.2] 24.5 [18.2–33.6] 46.4 [33.6–161.0]
Number cases/non-cases 90/574 131/648 142/686
Model 1 1.0 1.11 (0.82; 1.50) 1.24 (0.92; 1.68) 0.18
Model 2 1.0 1.05 (0.76; 1.44) 1.15 (0.83; 1.58) 0.43
Model 3 1.0 1.03 (0.75; 1.42) 1.11 (0.81; 1.54) 0.53
*Hazard ratios (HR) and 95% confidence intervals (CI) were estimated by Cox proportional hazard models. Models contained continuous variables unless otherwise
indicated.
Model 1: adjusted for age, sex and survey; model 2: adjusted for factors in model 1+BMI, systolic blood pressure, ratio of total cholesterol/HDL cholesterol, history of
diabetes, smoking status (never smoker, former smoker, current smoker), alcohol consumption (0, 0.1–39.9,$40 g/d for men; 0, 0.1–19.9, $20 g/d for women), physical
activity (inactive, active) and parental history of myocardial infarction (negative, positive, unknown); model 3: adjusted for factors in model 2+CRP and IL-6.
doi:10.1371/journal.pone.0025734.t001
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Athero-Express biobank study
Baseline characteristics of the Athero-Express biobank study
participants and RANTES protein levels in carotid plaques
stratified by clinical variables are shown in Tables 5 and 6. In
an unadjusted analysis, RANTES plaque levels were lower in
women compared to men and in patients with diabetes compared
to non-diabetic individuals, whereas no differences were seen for
other anthropometric or metabolic parameters such as BMI,
hypertension or hypercholesterolaemia. Among the cardiovascular
parameters, the presence of bilateral stenosis was associated with
higher RANTES levels, whereas no differences could be detected
for histories of vascular intervention or myocardial infarction.
Increased RANTES plaque levels were also associated with
increased systemic CRP levels.
At the histological level, RANTES plaque levels were higher in
plaques with less pronounced calcification (p= 0.009) and there
was a trend toward higher RANTES levels in plaques with
increased macrophage infiltration (p= 0.054), suggesting an
association between high RANTES levels and an unstable plaque
phenotype. We also found a trend for an association between
RANTES levels and lipid content, but not with smooth muscle cell
infiltration, collagen content, or presence of plaque haemorrhage
(Table 7).
During a mean follow-up of 2.8 years (SD 0.8 years, maximum
3 years), 51 study participants (8.5%) reached a cardiac endpoint
(cases). These included 31 individuals who died and 20 individuals
who underwent a cardiac intervention due to coronary artery
disease. RANTES plaque levels did not differ between individuals
without and with events (median [25th percentile, 75th percentile]
44.86 [29.04–74.96] vs 57.77 [34.52–79.90] ng/mg; respectively;
p = 0.12). When the event rates of individuals with high (above the
median of 45.52 ng/mg) and low (,45.52 ng/mg) RANTES levels
in plaques were compared, unadjusted Cox regression analysis
revealed no association with higher event risk for higher RANTES
levels (HR [95% CI] 1.51 [0.86–2.64], p = 0.16) (Fig. 1, Table 8).
Adjustment for baseline determinants of RANTES levels (i.e., sex,
Table 2. Frequencies of CCL5 genotypes in the subcohort and hazard ratios (HR) and 95% confidence intervals (CI) for incident
coronary events comparing CCL5 genotypes in the case-cohort dataset (MONICA/KORA Augsburg case-cohort study).
SNP Allele* n*
Weighted
frequency (%)* Model** HR (95% CI) for genotype*
1/2 11/12/22 11/12/22 11 12 22
rs2107538 C/T 1382/661/76 65.2/31.2/3.6 1 1 (ref) 1.06 (0.81–1.37) 0.98 (0.52–1.84)
2 1 (ref) 1.04 (0.79–1.37) 1.13 (0.61–2.09)
rs2280788 C/G 2036/90/0 95.8/4.2/0 1 1 (ref) 0.55 (0.26–1.13) N/A
2 1 (ref) 0.57 (0.26–1.23) N/A
rs2280789 T/C 1601/488/40 75.2/22.9/1.9 1 1 (ref) 1.01 (0.76–1.33) 0.80 (0.30–2.11)
2 1 (ref) 0.99 (0.73–1.33) 0.96 (0.39–2.40)
rs4796120 A/G 1691/414/30 79.2/19.4/1.4 1 1 (ref) 1.02 (0.68–1.53) 0.96 (0.29–3.15)
2 1 (ref) 0.95 (0.61–1.48) 0.96 (0.29–3.15)
rs3817655 T/A 1380/665/80 64.9/31.3/3.8 1 1 (ref) 1.06 (0.81–1.37) 0.83 (0.44–1.58)
2 1 (ref) 1.04 (0.79–1.37) 0.81 (0.40–1.65)
rs1065341 A/G 1880/231/11 88.6/10.9/0.5 1 1 (ref) 1.00 (0.74–1.34) 1.08 (0.39–2.98)
2 1 (ref) 0.98 (0.72–1.34) 1.28 (0.50–3.31)
*Allele 1 denotes the major allele, allele 2 denotes the minor allele. All alleles are shown in forward orientation according to dbSNP BUILD 133.
**Model 1: adjusted for age, sex and survey; Model 2: Model 1+BMI, systolic blood pressure, ratio of total cholesterol / HDL cholesterol, smoking status, alcohol intake,
physical activity, history of diabetes.
N/A, not applicable (no homozygous carriers of the minor allele); ref, reference genotype.
doi:10.1371/journal.pone.0025734.t002
Table 3. CCL5 haplotype frequencies in the subcohort and association of haplotypes with RANTES serum levels and incident
coronary events (MONICA/KORA Augsburg case-cohort study).
Haplotype* Frequency Association with ln (RANTES)*** Association with incident coronary events:
(%) b (P) HR (95% CI)***
CCTATA 80.8 Reference Reference
TCCGAA 11.0 20.173 (4.961029) 1.05 (0.80–1.37)
TCTAAG 5.7 20.106 (0.0028) 1.05 (0.74–1.48)
TGCAAA 2.0 20.073 (0.24) 0.55 (0.26–1.18)
Rare (all other)** 0.3 20.137 (0.19) 4.04 (1.26–12.89)
*Haplotypes are based on SNPs rs2107538- rs2280788– rs2280789– rs4796120– rs3817655–rs1065341. Minor alleles of the respective SNPs are underlined.
**The category ‘rare haplotypes’ contains all haplotypes with a frequency of ,1% in the subcohort.
***Adjusted for age, sex and survey. b, regression coefficients.
doi:10.1371/journal.pone.0025734.t003
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diabetes status, presence of bilateral stenosis, CRP) attenuated the
association even further (HR [95% CI] 1.01 [0.99–1.01];
p = 0.87).
Discussion
Our study has three main findings: (i) RANTES serum levels
were not associated with incident coronary events in the
MONICA/KORA Augsburg case-cohort study, (ii) functional
RANTES/CCL5 SNPs were not associated with CAD in the large
CARDIoGRAM study, and (iii) RANTES levels were associated
with an unstable phenotype of carotid plaques, but no independent
predictor of future coronary events in the Athero-Express study.
RANTES serum levels and incident CHD
Prospective studies on systemic RANTES levels and cardiovas-
cular outcomes are very scarce and controversial. Whereas higher
2-year cardiac mortality in male patients undergoing coronary
angiography has been found associated with reduced levels of
RANTES plasma levels [44], elevated RANTES levels predicted
future cardiovascular events in a small sample of patients with
unstable angina pectoris [45]. In patients with acute coronary
syndromes RANTES plasma levels were – in contrast to
concentrations of most other biomarkers measured - not predictive
of future cardiovascular events [46]. In all three studies, the
number of incident cases was substantially lower than in the
MONICA/KORA Augsburg case-cohort study, and follow-up
periods were shorter. Furthermore, these aforementioned studies
were performed in subjects with suspected and/or preexisting
cardiovascular disease, which limits the conclusions that can be
drawn regarding cardiovascular risk in the general population.
Therefore, our prospective MONICA/KORA Augsburg case-
cohort study extends the current literature as it represents the first
large, population-based study to characterise the relationship
Table 4. Frequencies of CCL5 alleles and allelic odds ratios (OR) and 95% confidence intervals (CI) for coronary artery disease in the
CARDIoGRAM study.
SNP n Allele 1/2* Frequency for allele 2 (%) OR (95% CI) for allele 2 p
rs2107538 81,687 T / C 84.4 0.98 (0.94–1.02) 0.26
rs2280788 21,119 G / C 13.0 1.06 (0.94–1.21) 0.34
rs2280789 82,387 T / C 12.4 1.04 (0.99–1.08) 0.092
rs4796120 80,590 A / G 11.1 1.04 (0.99–1.09) 0.11
rs3817655 61,650 T / A 15.8 1.04 (1.003–1.09) 0.035
rs1065341 80,935 A / G 7.5 1.03 (0.95–1.10) 0.51
*All alleles are shown in forward orientation according to dbSNP BUILD 133.
doi:10.1371/journal.pone.0025734.t004
Table 5. Baseline characteristics (demographic, anthropometric and metabolic data) related to the plaque specimens of the
Athero-Express biobank study.
Patient characteristics n (%) RANTES (ng/mg) p
Median [IQR]
Age (mean 68.3, SD 8.9, range 37.5–91.1 yrs)
Sex
Male 427 (70.5%) 46.7 [30.6–78.3] 0.05
Female 179 (29.5%) 42.7 [27.3–66.0]
Body mass index (mean 26.4, SD 3.8, range 15.2–50.7 kg/m2)
BMI,25 kg/m2 195 (36.8%) 45.2 [27.9–73.9] 0.21
BMI.25 kg/m2 335 (63.2%) 47.4 [30.6–78.3]
Hypercholesterolaemia
No 249 (41.2%) 46.4 [30.9–77.8] 0.49
Yes 356 (58.8%) 45.0 [28.2–74.3]
CRP (median 3.1, IQR 1.5–6.5 mg/l)*
,10.0 mg/l 272 (83.6%) 45.9 [30.5–75.4] 0.025
.10.0 mg/l 53 (16.3%) 58.0 [34.8–94.4]
Current smoker
No 433 (73.9%) 45.4 [29.1–75.2] 0.28
Yes 153 (26.1%) 47.4 [31.6–81.1]
RANTES levels are expressed as median and interquartile range [IQR; 25th percentile–75th percentile].
*Systemic CRP levels were available for a subgroup of the study participants (n = 325).
doi:10.1371/journal.pone.0025734.t005
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between systemic RANTES concentrations and cardiovascular
outcomes.
RANTES/CCL5 SNPs and cardiovascular risk
In recent years, several candidate studies analysed whether
CCL5 SNPs could serve as biomarkers for cardiovascular risk.
Most data are available for the CCL5 SNP rs2107538 which is also
known as 2403GA. This SNP is likely to be functional as we
showed in the MONICA/KORA cohort before that carriers of
the minor allele had significantly lower RANTES serum levels
[38]. Alleles or genotypes of rs2107538 were associated with CAD
in patients who underwent coronary angiography [47], with all-
cause mortality (mainly attributable to cardiac events) in patients
with type 2 diabetes and end-stage renal disease [48] and with
presence and severity of CAD in patients subjected to percutane-
ous coronary intervention [49]. In contrast, rs2107538 variants
showed no associations with CAD in a case-control study [50] or
with presence of significant (.50%) stenosis in patients who
underwent elective coronary angiography [51]. Overall, these data
were inconclusive with regard to associations between rs2107538
and cardiovascular disease, were confined to patient groups and
therefore cannot be extrapolated to the general population.
Given the low statistical power of the aforementioned single
studies it is of interest that associations with genome-wide
significance have not been reported for SNPs in or near the
CCL5 locus in recent GWAS that covered this genomic region
[27,52,53,54]. However, from these reports it was not clear
whether this lack of evidence was most likely due to an absence of
any association or whether results for SNPs in/near this locus
suggested that genome-wide significance could be reached by a
reasonable increase in sample size.
The data from the MONICA/KORA study represent the first
report on associations between CCL5 genotypes and incident
coronary events from a population-based study. Due to limited
statistical power we sought to substantiate our findings in the
CARDIoGRAM consortium, currently the largest database on
gene variants and CAD worldwide. As recently published, the
CARDIoGRAM study is adequately powered to reveal associa-
tions at genome-wide significance level (p,561028) between
common SNPs and CAD even for allelic OR of ,1.10 [27], but
associations between CCL5 genotypes and CAD were not
nominally significant and far from genome-wide significance. It
should be noted that in contrast to the prospective MONICA/
KORA Augsburg case-cohort that evaluated risk factors for
incident coronary events the CARDIoGRAM study investigated
gene variants that are associated with prevalent CAD and thus
does not represent a perfect replication sample. However, we
believe that any major impact of RANTES genotypes on coronary
risk should also have been reflected by an association with
prevalent disease so that the CARDIoGRAM data add relevant
information to the initial findings from the MONICA/KORA
Augsburg case-cohort study.
The MONICA/KORA Augsburg study also allowed for the
evaluation of haplotypes as risk factors of coronary events. Our
data indicate that rare haplotypes may indeed comprise variants
that are associated with increased coronary risk. However, this
study does not have the statistical power to analyse this aspect in
more detail, and data on DNA sequences would be needed to
identify defined haplotypes with potential relevance for pathogen-
esis and prediction. Therefore, this finding is hypothesis-generat-
ing at best and needs corroboration in further studies.
Taken together, our data strongly suggest that the six CCL5
SNPs that we included in our study and the major haplotypes
based on them may not be relevant biomarkers for the prediction
of cardiovascular events.
Predictive value of RANTES protein levels in plaques
Data from mouse models demonstrate that RANTES and its
receptor CCR5 are expressed in atheromas, that they play a causal
role in atherogenesis in these models and that interference with
leukocyte migration at this level may represent a promising
therapeutic approach to prevent or delay atherosclerotic processes
[5]. Hence, it can be hypothesised that higher RANTES levels
may be indicative of elevated cardiovascular risk.
Higher CCL5 gene expression has indeed been reported in
atherosclerotic tissue from individuals with symptomatic carotid
plaques (i.e., symptoms within the past 6 months) compared to
CCL5 gene expression in iliac arteries from organ donors [55]. In
contrast, several chemokines were upregulated in downstream
compared to upstream portions of carotid plaques in patients
Table 6. Baseline characteristics (clinical data and
medication) related to the plaque specimens of the Athero-
Express biobank study.
Patient characteristics n (%) RANTES (ng/mg) p
Median [IQR]
Diabetes mellitus
No 493 (81.5%) 47.4 [30.1–78.3] 0.03
Yes 112 (18.5%) 40.1 [28.3–60.4]
Hypertension
No 197 (32.6%) 45.4 [31.7–79.6] 0.22
Yes 407 (67.4%) 45.8 [27.6–73.6]
History of vascular
intervention
No 404 (66.8%) 46.4 [30.4–75.8] 0.66
Yes 201 (33.2%) 44.6 [28.3–74.8]
History of myocardial
infarction
No 483 (80.0%) 45.6 [29.5–76.6] 0.72
Yes 120 (20.0%) 45.5 [29.4–74.0]
Bilateral stenosis
No 344 (56.8%) 42.3 [26.2–67.6] 0.001
Yes 262 (43.2%) 50.6 [33.0–81.2]
Statin use
No 164 (27.1%) 50.2 [30.8–85.2] 0.16
Yes 441 (72.9%) 45.1 [29.3–73.3]
Aspirin use
No 61 (10.1%) 47.0 [27.8–82.6] 0.48
Yes 544 (89.9%) 45.5 [29.9–74.4]
Oral anticoagulant use
No 522 (86.3%) 45.6 [30.0–75.0] 0.88
Yes 83 (13.7%) 45.5 [28.1–80.3]
Clinical presentation
Asymptomatic 104 (17.2%) 48.1 [29.8–77.3] 0.63
Symptomatic (AFX, TIA or
stroke)
502 (82.8%) 45.0 [29.4–75.5]
RANTES levels are expressed as median and interquartile range [IQR; 25th
percentile–75th percentile]. AFX, amaurosis fugax; TIA, transient ischaemic
attack.
doi:10.1371/journal.pone.0025734.t006
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undergoing carotid endarterectomy for extracranial high-grade
internal carotid stenosis, but no differences in gene expression
could be seen for CCL5 [56]. In the Atherosclerosis Risk in
Communities (ARIC) Carotid MRI study, RANTES plasma levels
were associated with the extent of atherosclerosis and high-risk
plaques, but RANTES levels in plaques were not measured in this
study [57].
Our findings from the Athero-Express study extend current
knowledge on RANTES plaque levels as potential biomarker
because it relates RANTES plaque levels and risk for coronary
events in a prospective design. Although we observed a trend
toward higher risk for higher RANTES plaque levels, this
association was completely abolished when we accounted for
several established cardiovascular risk factors in a multivariate
analysis. However, it should be noted that we found an association
between RANTES and an unstable plaque phenotype which is in
line with previous studies investigating the potential role of
RANTES in the development of cardiovascular disease. It is
noteworthy that some of the classical cardiovascular risk factors
such as male sex, diabetes or systemic CRP were not significantly
associated with the risk for coronary events in the multivariate
model. We hypothesise that both the low number of events
(compared to studies like the MONICA/KORA Augsburg case-
cohort study) and the fact that the study sample represents a high-
risk group that differs from the general population may have
contributed to this finding.
Strengths of our study
The combination of three independent studies to investigate
different biological levels (gene variants, local and systemic protein
concentrations) of RANTES in order to assess their use as
potential biomarkers for the risk of coronary events represents the
Table 7. RANTES expression levels (median [25th percentile–75th percentile] in ng/mg in relation to histological plaque
composition of atherosclerotic carotid plaques (Athero-Express biobank study).
Macrophage
infiltration
Smooth muscle
cell infiltration Calcification
Collagen
content
Lipid core
size*
Plaque
haemorrhage**
No 41.4 [29.6–61.5] 55.4 [27.3–84.0] 48.8 [32.9–79.6] - 39.1 [24.3–65.4] 42.7 [27.5–71.2]
Minor 44.9 [27.9–71.7] 47.9 [32.2–80.0] 48.9 [29.0–78.4] 52.4 [31.6–89.0] 47.6 [30.7–82.4] 46.4 [30.0–76.6]
Moderate 44.7 [29.1–75.3] 44.9 [29.5–70.4] 48.4 [30.6–74.1] 44.9 [29.5–72.3] 46.9 [30.6–70.9]
Heavy 58.4 [33.1–83.2] 44.5 [25.8–84.4] 38.0 [25.5–67.7] 43.7 [27.3–74.7]
Correlation
coefficient
0.08 20.18 20.11 20.05 0.07 20.96
P 0.054 0.66 0.009 0.24 0.09 0.34
Correlations of the histological plaque characteristics with continuous RANTES levels were analysed by Spearman’s bivariate correlation test.
*Lipid core size was expressed as no, ,40% and .40% of the total plaque area.
**Presence of plaque haemorrhage was scored as present or absent and statistically analysed by the Mann Whitney-U test.
doi:10.1371/journal.pone.0025734.t007
Figure 1. Unadjusted relationship between RANTES levels in carotid plaques and cardiac clinical outcome (Athero-Express biobank
study).
doi:10.1371/journal.pone.0025734.g001
RANTES/CCL5 and Incident Coronary Events
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e25734
main strength of our study. Our findings are based on study
cohorts that have been used before to identify novel associations
between inflammation-related proteins (MONICA/KORA,
Athero-Express), gene variants (CARDIoGRAM) and cardiovas-
cular risk. The MONICA/KORA study is the first population-
based study to examine the relationship between CCL5 SNPs,
RANTES serum levels and risk for coronary events. Its strengths
include the population-based design, a long follow-up and a large
number of cases. The Athero-Express study also represents the
first study to test whether RANTES plaque levels predict
cardiovascular outcome. The fact that the same cohort and the
same methods allowed us to identify other prognostic proteins in
carotid plaques such as fatty-acid binding protein, matrix
metalloproteinase-8 and osteopontin as predictors of cardiovas-
cular events underlines that the study design is indeed suitable to
address our study question [29–31]. The CARDIoGRAM
database is currently the largest database worldwide on common
SNPs and CAD and thus the best available data source for our
study aim.
Study limitations
In the MONICA/KORA Augsburg case-cohort study we
measured RANTES in serum samples which is important to note
because RANTES is released by platelets during the clotting
process. Therefore, we cannot exclude that the analysis of platelet-
poor or platelet-free plasma would have led to different results.
Platelet count is only available in MONICA/KORA survey 3, so
that we could not adjust for this potentially relevant confounder in
our analysis. A general limitation of current studies on RANTES
and disease outcomes, including our own (MONICA/KORA and
Athero-Express), is the fact that commercially available assays
measure total RANTES protein, although variant forms including
truncated proteins and proteins with different oxidation, glycation
and glycosylation patterns exist. More research is needed to reveal
whether these variants may be more informative in prospective
studies than total RANTES levels [58]. Finally, the CARDIo-
GRAM consortium combined studies with different designs and
outcome definitions which can be expected to attenuate
associations between genetic variation and risk for coronary
events.
Conclusion
We found an association between high RANTES plaque levels
and an unstable plaque phenotype, but no associations of (i)
RANTES serum levels, (ii) CCL5 genotypes and (iii) RANTES
content in carotid plaques with coronary artery disease or incident
coronary events in our cohorts. These data indicate that
RANTES/CCL5 gene variants and protein levels may not be
novel biomarkers for the risk of coronary events in humans.
However, our study could not address the questions whether
measurement of RANTES in platelet-poor plasma or measure-
ment of variant forms of RANTES proteins (locally or systemi-
cally) may be more informative for cardiovascular risk prediction
than the approaches we pursued. Moreover, we cannot exclude
that the measurement of RANTES may be of prognostic benefit in
specific patient groups.
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Table 8. Risk of coronary events according to baseline plaque levels of RANTES (Athero-Express Biobank Study).
Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
RANTES (above vs below median) 1.51 (0.86–2.64) 0.16 1.01 (0.99–1.01) 0.87
Sex (men vs women) 2.55 (1.15–5.56) 0.02 2.10 (0.80–5.53) 0.13
Diabetes (yes vs no) 1.60 (0.85–3.00) 0.15 2.05 (0.87–4.82) 0.10
Bilateral stenosis (yes vs no) 1.46 (0.84–2.53) 0.18 1.61 (0.77–3.39) 0.21
CRP (mg/l) 1.01 (1.00–1.02) 0.16 1.01 (0.99–1.02) 0.22
Data are given as hazard ratios (HR) and 95% confidence intervals (CI).
doi:10.1371/journal.pone.0025734.t008
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